A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants

BACKGROUND: The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor (NNRTI) that binds to reverse transcriptase (RT) and allosterically blocks the chemical step of DNA synthesis. In contrast to earlier NNRTIs, rilpivirine retains potency against well-character...

詳細記述

保存先:
書誌詳細
主要な著者: Johnson, Barry C, Pauly, Gary T, Rai, Ganesha, Patel, Disha, Bauman, Joseph D, Baker, Heather L, Das, Kalyan, Schneider, Joel P, Maloney, David J, Arnold, Eddy, Thomas, Craig J, Hughes, Stephen H
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2012
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3549755/
https://ncbi.nlm.nih.gov/pubmed/23217210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-4690-9-99
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料